Kevin D. Freeman‐Cook

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 186 citations

Life Sciences, Cancer Biology, Oncology +14

Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A

Casey L. Quinlan, Stephen E. Kaiser, Ben Bolaños et al. · Nature Chemical Biology · 2017 · 132 citations

Life Sciences, Biochemistry, Medicinal Chemistry +14

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 117 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Design of Selective, ATP-Competitive Inhibitors of Akt

Kevin D. Freeman‐Cook, Christopher Autry, Gary Borzillo et al. · Journal of Medicinal Chemistry · 2010 · 77 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

Pharmacy, Biochemistry, Medicinal Chemistry +12